CES 2012 Video Coverage! Social Network: ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Forums: www.iPhoneForums.net Facebook on.fb.me Twitter: www.Twitter.com Google+: bit.ly

Common Market Connect For Check Out Halos One www.facebook.com

Waldo and Dash Common Market Connect Four Instrumental no copyright intended Waldo- www.facebook.com Dash- www.facebook.com

Register for this CCAR Seminar here: tinyurl.com The Contra Costa Association of Realtors sponsors workshops and seminars that enable Realtors and business owners to be successful with social media and online marketing. fb.com These classes always include a tremendous amount of information on exactly what you should do, why it works, and how to get started. Each class offers a collection of tips, strategies and tools available to you in the world of social media and internet marketing The first seminar in this series is "How to Engage Your Market, Connect With Customers and Grow Your Business" Bring your notepad, curiosity and questions and learn some of the most effective social media and online marketing strategies, resources and best practices for attracting more business and sales The first seminar in this series of seven classes is FREE...In this introductory seminar we cover these topics... Blogs and websites LinkedIn YouTube and video marketing Mobile media and text message marketing Google Twitter Facebook Zillow Active Rain Craigslist And how to integrate traditional print media marketing The other upcoming seminars include... "How to Build Your LinkedIn Foundation to Grow Your Business" In this seminar you will discover... How to Optimize Your LinkedIn Profile for maximum exposure and top search ranking using targeted keywords The secrets to leveraging LinkedIn Recommendations Tips on integrating LinkedIn into the rest of your Social Media Strategy The "How to ...

Doug Reynolds, a Sacramento Area Realtor, discusses the local real estate market while looking back at 2011. He highlights the flat median sales price, extremely low inventory, buyer competition, high sales volume and the current "Price Sensitive Sellers Market." This is a great video for buyers are sellers to get a quick update on what happened during 2011 in the local market. Remember, real estate is mostly a local issue; you cannot listen to the national news and trust that is what is happening in your market. Connect with Doug Reynolds on Facebook, follow his informative blog and subscribe to his YouTube channel.

The newly released FPS title "Battlefield 3" incorporates many aspects in a video game that have never before been used. The technology and capabilities of the Frostbite 2.0 Engine are far more sophisticated and advanced than any other FPS on the market. Connect With VidThru.com: www.youtube.com www.own3d.tv Follow Sven-D: YouTube: www.youtube.com Facebook: www.facebook.com Twitter: twitter.com

Chief Scientific Officer (CSO) for OmniBio Dr. Charles Dinarello discusses Alpha-1 Antitrypsin (AAT) research and it's potential as a therapy for Type 1 diabetes. He is also a Professor of Medicine and Immunology at the University of Colorado Denver who has published over 700 original research articles on cytokines, particularly interleukin‐1 (IL‐1) and tumor necrosis factor, and is considered a "founding father" of cytokine biology. OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com

Dr. Charles Dinarello, Chief Scientific Officer of OmniBio, is a co-author of an article that is now available in the journal Blood, which is the premier journal of the American Society of Hematology. The paper describes the use of Alpha 1 antitrypsin (AAT) to treat mice with a lethal form of rejection of bone marrow transplantation. Mice survive the crisis with AAT treatment. OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com

Leveraged loan volume, default rates, yields and returns are featured in this monthly video analysis of the US leveraged loan market. Also: a detailed look at the burgeoning CLO market. Connect with LCD Download the slides for this video (free) at Slideshare.net! ow.ly Connect with LCD Facebook: www.lcdcomps.com Like LCD on Facebook for monthly analysis on LBO/Private equity stats, as well as Default/Restructuring analysis. LinkedIn: www.lcdcomps.com There's almost 6000 market contacts in LCD's Leveraged Loan Group Twitter: www.twitter.com News, commentary, other leveraged finance info Web: www.lcdcomps.com

OmniBio CEO Dr. James Crapo talks about the important research taking place with Alpha-1 Antitrypsin (AAT). This safe and powerful molecule is being used in trials for type 1 diabetes and Graph vs. Host disease (GVH). OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com